Larcaviximab Biosimilar - Research Grade

Human

Zaire Ebola virusï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Antibodies directed against the Zaire Ebola virus glycoprotein are central tools for filovirus neutralization research and vaccine evaluation. This human IgG1, kappa reagent is an unconjugated, non-therapeutic analog of larcaviximab that recognizes the Zaire Ebola virus antigen for functional and infectious-disease studies. It is prepared in a low-endotoxin format suited to in vivo experiments and manufactured at scalable milligram-to-gram volumes to keep bulk and high-throughput pipelines supplied. Provided for research use only (RUO), it is appropriate as a positive binding control and active reagent in neutralization assays, antigen-detection panels, and preclinical models of filovirus infection.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks